GlassScriptPhysician profile
Paul M Jost
NPI 1720018716
$6,462.08
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,114 · 2020: $1,413 · 2021: $1,607 · 2022: $1,329.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,166.49 | 2019-2022 | |
| Viiv Healthcare Company | $998.30 | 2019-2022 | |
| Gilead Sciences, INC. | $687.61 | 2019-2022 | |
| Janssen Biotech, INC. | $604.45 | 2019-2022 | |
| Insmed, INC. | $526.84 | 2019-2022 | |
| Melinta Therapeutics, LLC | $499.20 | 2019-2022 | |
| Napo Pharmaceuticals INC | $295.86 | 2019-2022 | |
| Abbvie INC. | $235.83 | 2021-2022 | |
| La Jolla Pharmaceutical Company | $209.43 | 2020-2022 | |
| Allergan, INC. | $178.59 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $161.00 | 2020-2022 | |
| Astellas Pharma US INC | $160.50 | 2019 | |
| Shionogi INC | $111.25 | 2021-2022 | |
| Shire North American Group INC | $108.72 | 2019 | |
| Janssen Products, LP | $99.00 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $81.93 | 2022 | |
| Theratechnologies INC. | $81.86 | 2019 | |
| Vyera Pharmaceuticals, LLC | $40.01 | 2020-2021 | |
| Tetraphase Pharmaceuticals, INC. | $35.04 | 2019-2020 | |
| Nabriva Therapeutics, Plc | $34.06 | 2021 | |
| Mylan Institutional INC. | $26.08 | 2019 | |
| Octapharma USA, INC. | $24.68 | 2020 | |
| Grifols USA, LLC | $20.10 | 2019 | |
| Pfizer INC. | $16.94 | 2019 | |
| Genentech USA, INC. | $15.82 | 2022 | |
| Paratek Pharmaceuticals, INC. | $14.99 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.01 | 2021 | |
| Adma Biomanufacturing LLC | $13.49 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Jost listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.